The separate, second flow path enables the development of diagnostic tests with increased sensitivity and extends the spectrum of useful sample types.

Chembio Diagnostics has been issued a U.S. patent for its “Dual Path Immunoassay Device.” The patent describes a device and method for detection that includes a separate, second flow path for application of the sample material to be tested versus other solutions used in developing lateral flow rapid tests.


This second flow path enables the development of diagnostic tests that can increase sensitivity, extends the spectrum of useful sample types beyond typical sources, such as blood, serum, and plasma, improves results when testing for multiple conditions and/or different parameters of one related condition, and reduces the amount of expensive reagents required, according to the company.


While Chembio Diagnostics awaits additional patent protection in the U.S. and worldwide, it is seeking collaborations for this technology platform.

Previous articleAdvanced Life Sciences’ Prophylactic for Inhaled Anthrax Granted Orphan Drug Designation
Next articleRoche Opts Out of Deal with Maxygen